Rilonacept

In today's world, Rilonacept has become a topic of great relevance and interest to a wide range of people. From its impact on society to its implications in the field of science, Rilonacept has captured the attention and curiosity of many. With endless aspects to explore, this article seeks to delve into the fascinating world of Rilonacept, analyzing its origins, evolution and repercussions in different areas. Along these lines, we will embark on a journey of discovery and reflection about Rilonacept, trying to shed light on its importance and its possible implications in the future.

Rilonacept
Clinical data
Trade namesArcalyst
Other namesIL-1 Trap
AHFS/Drugs.comMonograph
License data
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC9030H13932N2400O2670S74
Molar mass201209.36 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.[1][2][3] Rilonacept is an interleukin 1 inhibitor.[4]

Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.[5]

Rilonacept was given an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome.[3][6] Rilonacept is the first drug approved by the FDA to treat recurrent pericarditis.[3] Rilonacept was approved for medical use in the United States in February 2008.[7]

On May 8, 2012, an FDA Advisory Panel voted 11–0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[8]

References

  1. ^ a b "Arcalyst- rilonacept injection, powder, lyophilized, for solution". DailyMed. Retrieved 18 March 2021.
  2. ^ a b "Rilonacept Regeneron (previously Arcalyst) EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 March 2021.
  3. ^ a b c "FDA Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart". U.S. Food and Drug Administration (FDA). 18 March 2021. Retrieved 18 March 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. (October 2009). "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study". Annals of the Rheumatic Diseases. 68 (10): 1613–7. doi:10.1136/ard.2009.108936. PMC 2732898. PMID 19635719.
  5. ^ "Molecule of the month. Rilonacept". Drug News & Perspectives. 21 (4): 232. May 2008. PMID 18560622.
  6. ^ "Arcalyst FDA Approval History - Drugs.com". Archived from the original on 2012-05-16. Retrieved 2012-05-08.
  7. ^ "Drug Approval Package: Arcalyst (Rilonacept) NDA #125249". U.S. Food and Drug Administration (FDA). 2 May 2008. Retrieved 20 March 2021.
  8. ^ "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". 8 May 2012. Archived from the original on 2012-05-21. Retrieved 2012-05-08.
  • "Rilonacept". Drug Information Portal. U.S. National Library of Medicine.